MX340577B - Inhibidor de fosfoinositida 3-quinasa con una porcion de enlace de cinc. - Google Patents

Inhibidor de fosfoinositida 3-quinasa con una porcion de enlace de cinc.

Info

Publication number
MX340577B
MX340577B MX2013011132A MX2013011132A MX340577B MX 340577 B MX340577 B MX 340577B MX 2013011132 A MX2013011132 A MX 2013011132A MX 2013011132 A MX2013011132 A MX 2013011132A MX 340577 B MX340577 B MX 340577B
Authority
MX
Mexico
Prior art keywords
phosphoinositide
kinase inhibitor
binding moiety
zinc binding
kinase
Prior art date
Application number
MX2013011132A
Other languages
English (en)
Other versions
MX2013011132A (es
Inventor
Cai Xiong
Zhai Haixiao
Lai Chengjung
Qian Changgeng
Bao Rudi
Original Assignee
Curis Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Curis Inc filed Critical Curis Inc
Publication of MX2013011132A publication Critical patent/MX2013011132A/es
Publication of MX340577B publication Critical patent/MX340577B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system having sulfur as a ring hetero atom, e.g. ticlopidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/166—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/28—Radicals substituted by singly-bound oxygen or sulphur atoms
    • C07D213/30—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La invención proporciona un compuesto de fórmula I, (Ver Formula) Composiciones farmacéuticas que comprenden dichos compuestos y el uso de dichos compuestos en el tratamiento de enfermedades y trastornos tales como el cáncer relacionadas con fosfoinositida 3-quinasa. La presente solicitud se relaciona además con el tratamiento de enfermedades y trastornos relacionados con histona deacetilasa y fosfoinositida 3-quinasa.
MX2013011132A 2011-04-01 2012-03-30 Inhibidor de fosfoinositida 3-quinasa con una porcion de enlace de cinc. MX340577B (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161470849P 2011-04-01 2011-04-01
US201161559489P 2011-11-14 2011-11-14
PCT/US2012/031361 WO2012135571A1 (en) 2011-04-01 2012-03-30 Phosphoinositide 3-kinase inhibitor with a zinc binding moiety

Publications (2)

Publication Number Publication Date
MX2013011132A MX2013011132A (es) 2014-03-12
MX340577B true MX340577B (es) 2016-07-13

Family

ID=46931927

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2013011132A MX340577B (es) 2011-04-01 2012-03-30 Inhibidor de fosfoinositida 3-quinasa con una porcion de enlace de cinc.

Country Status (29)

Country Link
US (7) US8710219B2 (es)
EP (2) EP3111938B1 (es)
JP (3) JP6242331B2 (es)
KR (2) KR101902325B1 (es)
CN (2) CN105461736B (es)
AU (1) AU2012236367B2 (es)
BR (1) BR112013025340B1 (es)
CA (1) CA2830822C (es)
CL (1) CL2013002823A1 (es)
CY (2) CY1117785T1 (es)
DK (2) DK3111938T3 (es)
EA (1) EA022434B9 (es)
ES (2) ES2733128T3 (es)
HR (2) HRP20160545T1 (es)
HU (2) HUE045041T2 (es)
IL (2) IL228588A (es)
LT (1) LT3111938T (es)
ME (2) ME03523B (es)
MX (1) MX340577B (es)
PE (1) PE20141382A1 (es)
PL (2) PL2694075T3 (es)
PT (2) PT3111938T (es)
RS (2) RS59219B1 (es)
SG (2) SG10201602569RA (es)
SI (2) SI3111938T1 (es)
SM (2) SMT201900435T1 (es)
TW (1) TWI571469B (es)
WO (1) WO2012135571A1 (es)
ZA (2) ZA201307082B (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2010203512C1 (en) 2009-01-08 2013-10-17 Curis, Inc. Phosphoinositide 3-kinase inhibitors with a zinc binding moiety
SG10201602569RA (en) 2011-04-01 2016-05-30 Curis Inc Phosphoinositide 3-kinase inhibitor with a zinc binding moiety
SG10201510307WA (en) 2011-11-14 2016-01-28 Cephalon Inc Uracil derivatives as axl and c-met kinase inhibitors
CN104725301A (zh) * 2013-12-20 2015-06-24 北京蓝贝望生物医药科技股份有限公司 一种1,2-二氢吡啶-2-酮衍生物的制备方法
JP6518833B2 (ja) * 2015-04-21 2019-05-22 ▲貴▼州百▲霊▼企▲業▼集▲団▼制▲薬▼股▲分▼有限公司Ｇｕｉｚｈｏｕ Ｂａｉｌｉｎｇ Ｇｒｏｕｐ Ｐｈａｒｍａｃｅｕｔｉｃａｌ Ｃｏ．，Ｌｔｄ． プリニル−ｎ−ヒドロキシルピリミジンホルムアミド誘導体、並びにその調製方法および使用
CN109476710B (zh) * 2016-07-19 2021-11-23 国立植物基因组研究所 抗真菌病原体的新蛋白质
WO2018085342A1 (en) * 2016-11-02 2018-05-11 Curis, Inc. Combination therapy with a phosphoinositide 3-kinase inhibitor with a zinc binding moiety
AU2018360845B2 (en) * 2017-11-06 2024-05-02 Cold Spring Harbor Laboratory Method and compositions for forming a copper-containing complex and uses thereof
MA53619A (fr) 2018-09-11 2021-12-15 Curis Inc Polythérapie avec un inhibiteur de phosphoinositide 3-kinase ayant une fraction de liaison au zinc
EP3968215A1 (en) 2020-09-09 2022-03-16 Koninklijke Philips N.V. Determining target object type and position
WO2023212574A1 (en) * 2022-04-26 2023-11-02 Olivia Szu Hsieh Lee Nakaya Compositions and methods for modulating rhythmic activity of pacemaker cardiomyocytes

Family Cites Families (64)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US4828991A (en) 1984-01-31 1989-05-09 Akzo N.V. Tumor specific monoclonal antibodies
US5369108A (en) 1991-10-04 1994-11-29 Sloan-Kettering Institute For Cancer Research Potent inducers of terminal differentiation and methods of use thereof
US5502187A (en) 1992-04-03 1996-03-26 The Upjohn Company Pharmaceutically active bicyclic-heterocyclic amines
US5497763A (en) 1993-05-21 1996-03-12 Aradigm Corporation Disposable package for intrapulmonary delivery of aerosolized formulations
US5508269A (en) 1994-10-19 1996-04-16 Pathogenesis Corporation Aminoglycoside formulation for aerosolization
US6777217B1 (en) 1996-03-26 2004-08-17 President And Fellows Of Harvard College Histone deacetylases, and uses related thereto
US6083922A (en) 1996-04-02 2000-07-04 Pathogenesis, Corp. Method and a tobramycin aerosol formulation for treatment prevention and containment of tuberculosis
US5767068A (en) 1997-02-13 1998-06-16 Pathogenesis Corporation Pure biologically active colistin, its components and a colistin formulation for treatment of pulmonary infections
CN1186324C (zh) 2000-04-27 2005-01-26 山之内制药株式会社 稠合杂芳基衍生物
US6608053B2 (en) 2000-04-27 2003-08-19 Yamanouchi Pharmaceutical Co., Ltd. Fused heteroaryl derivatives
PL220783B1 (pl) 2002-03-13 2016-01-29 Janssen Pharmaceutica Nv Pochodna sulfonylowa, jej zastosowanie i sposób wytwarzania oraz kompozycja farmaceutyczna
ES2347544T3 (es) 2002-03-13 2010-11-02 Janssen Pharmaceutica Nv Inhibidores de histona-desacetilasas.
WO2003076395A1 (en) 2002-03-13 2003-09-18 Janssen Pharmaceutica N.V. Carbonylamino-derivatives as novel inhibitors of histone deacetylase
AU2003209727B2 (en) 2002-03-13 2008-10-16 Janssen Pharmaceutica N.V. Sulfonylamino-derivatives as novel inhibitors of histone deacetylase
WO2004017950A2 (en) 2002-08-22 2004-03-04 Piramed Limited Phosphadidylinositol 3,5-biphosphate inhibitors as anti-viral agents
SI1591446T1 (sl) 2003-01-29 2013-07-31 Takeda Pharmaceutical Company Limited Tienopiridinske spojine in njihova uporaba
US8227636B2 (en) * 2004-04-05 2012-07-24 Merck Hdac Research, Llc Histone deacetylase inhibitor prodrugs
AU2005249380C1 (en) 2004-04-23 2012-09-20 Exelixis, Inc. Kinase modulators and methods of use
WO2006040966A1 (ja) 2004-10-08 2006-04-20 Astellas Pharma Inc. 芳香環縮合ピリミジン誘導体
GB0423653D0 (en) 2004-10-25 2004-11-24 Piramed Ltd Pharmaceutical compounds
EP2522396A1 (en) 2005-02-03 2012-11-14 TopoTarget UK Limited Combination therapies using HDAC inhibitors
EP1885710B1 (en) 2005-05-18 2015-08-19 Janssen Pharmaceutica N.V. Substituted aminopropenyl piperidine or morpholine derivatives as novel inhibitors of histone deacetylase
US7888360B2 (en) 2006-01-19 2011-02-15 Janssen Pharmaceutica N.V. Pyridine and pyrimidine derivatives as inhibitors of histone deacetylase
JP5247470B2 (ja) 2006-01-19 2013-07-24 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ ヒストンデアセチラーゼのインヒビターとしてのピリジン及びピリミジン誘導体
AU2007206941B2 (en) 2006-01-19 2012-09-13 Janssen Pharmaceutica N.V. Heterocyclylalkyl derivatives as novel inhibitors of histone deacetylase
EP2046799B1 (en) 2006-04-26 2017-07-19 Genentech, Inc. Phosphoinositide 3-kinase inhibitor compounds and pharmaceutical compositions containing them
CA2650290C (en) 2006-04-26 2015-11-17 Genentech, Inc. Pharmaceutical compounds
PT2024372E (pt) 2006-04-26 2010-09-16 Hoffmann La Roche Derivado de tieno[3,2-d]pirimidina útil como inibidor de pi3k
WO2007131364A1 (en) 2006-05-16 2007-11-22 Mcgill University Hybrid molecules having mixed vitamin d receptor agonism and histone deacetylase inhibitory properties
US20080161320A1 (en) 2006-09-11 2008-07-03 Xiong Cai Fused bicyclic pyrimidines as ptk inhibitors containing a zinc binding moiety
CA2662617C (en) 2006-09-11 2014-11-18 Changgeng Qian Quinazoline based egfr inhibitors containing a zinc binding moiety
AU2007296744A1 (en) 2006-09-11 2008-03-20 Curis, Inc. Multi-functional small molecules as anti-proliferative agents
CA2663147A1 (en) 2006-09-11 2008-03-20 Curis, Inc. Substituted 2-indolinone as ptk inhibitors containing a zinc binding moiety
AU2007296743B2 (en) 2006-09-11 2012-02-16 Curis, Inc. Tyrosine kinase inhibitors containing a zinc binding moiety
US7547781B2 (en) 2006-09-11 2009-06-16 Curis, Inc. Quinazoline based EGFR inhibitors containing a zinc binding moiety
WO2008055068A2 (en) 2006-10-28 2008-05-08 Methylgene Inc. Inhibitors of histone deacetylase
RU2470936C2 (ru) 2006-12-07 2012-12-27 Дженентек, Инк. Соединения-ингибиторы фосфоинозитид 3-киназы и способы применения
MY180595A (en) 2006-12-07 2020-12-03 Genentech Inc Phosphoinositide 3-kinase inhibitor compounds and methods of use
BRPI0807812A2 (pt) 2007-02-15 2020-06-23 Novartis Ag Combinações de lbh589 com outros agentes terapêuticos para tratar câncer
EP2136809A4 (en) 2007-03-20 2012-01-04 Curis Inc INHIBITORS OF RAF KINASE CONTAINING A ZINC BINDING FRAGMENT
WO2009036057A1 (en) 2007-09-10 2009-03-19 Curis, Inc. Antiproliferative agents containing a zinc binding moiety
TW200922564A (en) 2007-09-10 2009-06-01 Curis Inc CDK inhibitors containing a zinc binding moiety
WO2009036066A1 (en) 2007-09-10 2009-03-19 Curis, Inc. Vegfr inhibitors containing a zinc binding moiety
WO2009036020A1 (en) 2007-09-10 2009-03-19 Curis, Inc. Mek inhibitors containing a zinc binding moiety
TW200922590A (en) 2007-09-10 2009-06-01 Curis Inc VEGFR inhibitors containing a zinc binding moiety
KR101584823B1 (ko) * 2007-09-12 2016-01-22 제넨테크, 인크. 포스포이노시타이드 3-키나제 저해제 화합물과 화학치료제의 배합물 및 이의 사용방법
WO2009042646A1 (en) 2007-09-24 2009-04-02 Curis, Inc. Anti-proliferative agents
CN101909631B (zh) * 2007-10-25 2012-09-12 健泰科生物技术公司 制备噻吩并嘧啶化合物的方法
US20090149511A1 (en) 2007-10-30 2009-06-11 Syndax Pharmaceuticals, Inc. Administration of an Inhibitor of HDAC and an mTOR Inhibitor
WO2009086012A1 (en) 2007-12-20 2009-07-09 Curis, Inc. Aurora inhibitors containing a zinc binding moiety
WO2010008847A2 (en) 2008-06-24 2010-01-21 Takeda Pharmaceutical Company Limited Pi3k/m tor inhibitors
WO2009155659A1 (en) 2008-06-27 2009-12-30 The University Of Queensland Combination therapy
US8196911B2 (en) 2008-10-27 2012-06-12 Honda Motor Co., Ltd. Adjustable rate subframe mount
AU2010203512C1 (en) 2009-01-08 2013-10-17 Curis, Inc. Phosphoinositide 3-kinase inhibitors with a zinc binding moiety
US8741295B2 (en) 2009-02-09 2014-06-03 Universite De La Mediterranee PD-1 antibodies and PD-L1 antibodies and uses thereof
CA2753285A1 (en) 2009-03-12 2010-09-16 Genentech, Inc. Combinations of phosphoinositide 3-kinase inhibitor compounds and chemotherapeutic agents for the treatment of hematopoietic malignancies
KR101489045B1 (ko) 2009-10-12 2015-02-02 에프. 호프만-라 로슈 아게 Ｐｉ3ｋ 억제자 및 ｍｅｋ 억제자의 조합
AU2011239537A1 (en) * 2010-04-16 2012-11-15 Curis, Inc. Treatment of cancers having K-ras mutations
SG10201602569RA (en) * 2011-04-01 2016-05-30 Curis Inc Phosphoinositide 3-kinase inhibitor with a zinc binding moiety
US20130102595A1 (en) 2011-04-15 2013-04-25 Curis, Inc. Treatment of cancers having k-ras mutations
SG10201606284UA (en) 2011-08-01 2016-09-29 Genentech Inc Methods Of Treating Cancer Using Pd-1 Axis Binding Antagonists And Mek Inhibitors
CN114796501A (zh) 2015-06-25 2022-07-29 免疫医疗公司 抗体与治疗剂的组合治疗癌症的方法
WO2018085342A1 (en) * 2016-11-02 2018-05-11 Curis, Inc. Combination therapy with a phosphoinositide 3-kinase inhibitor with a zinc binding moiety

Also Published As

Publication number Publication date
JP6242331B2 (ja) 2017-12-06
JP2014509653A (ja) 2014-04-21
SMT201600179B (it) 2016-08-31
HRP20191091T1 (hr) 2019-09-20
HRP20160545T1 (hr) 2016-06-17
SG193563A1 (en) 2013-11-29
EA201301114A1 (ru) 2014-04-30
SMT201900435T1 (it) 2019-09-09
US9657032B2 (en) 2017-05-23
US20220168284A1 (en) 2022-06-02
IL248597B (en) 2018-04-30
EA022434B9 (ru) 2016-02-29
ME02451B (me) 2016-09-20
ZA201307082B (en) 2015-04-29
EP3111938B1 (en) 2019-05-08
IL228588A (en) 2016-11-30
ES2577982T3 (es) 2016-07-19
CY1121825T1 (el) 2020-07-31
US9249156B2 (en) 2016-02-02
JP6275784B2 (ja) 2018-02-07
PL3111938T3 (pl) 2019-09-30
US11654136B2 (en) 2023-05-23
US20130090335A1 (en) 2013-04-11
EP2694075A4 (en) 2014-10-01
AU2012236367A1 (en) 2013-04-18
SI2694075T1 (sl) 2016-07-29
MX2013011132A (es) 2014-03-12
CN103582483B (zh) 2016-02-17
US10111864B2 (en) 2018-10-30
WO2012135571A1 (en) 2012-10-04
CN105461736A (zh) 2016-04-06
EP2694075B1 (en) 2016-04-27
CL2013002823A1 (es) 2014-04-11
EP3111938A1 (en) 2017-01-04
PL2694075T3 (pl) 2016-09-30
ZA201406167B (en) 2015-03-25
PT3111938T (pt) 2019-07-10
AU2012236367B2 (en) 2014-10-09
US20140243330A1 (en) 2014-08-28
CN105461736B (zh) 2018-06-12
RS54903B1 (sr) 2016-10-31
NZ705039A (en) 2016-03-31
LT3111938T (lt) 2019-06-25
SI3111938T1 (sl) 2019-08-30
TWI571469B (zh) 2017-02-21
HUE028910T2 (en) 2017-01-30
HUE045041T2 (hu) 2019-12-30
TW201247678A (en) 2012-12-01
RS59219B1 (sr) 2019-10-31
US10543197B2 (en) 2020-01-28
US20200215039A1 (en) 2020-07-09
DK3111938T3 (da) 2019-07-01
CA2830822C (en) 2018-10-02
US20170304279A1 (en) 2017-10-26
ES2733128T3 (es) 2019-11-27
IL228588A0 (en) 2013-12-31
CN103582483A (zh) 2014-02-12
IL248597A0 (en) 2016-12-29
US8710219B2 (en) 2014-04-29
US20190091211A1 (en) 2019-03-28
CY1117785T1 (el) 2017-05-17
ME03523B (me) 2020-04-20
BR112013025340B1 (pt) 2021-12-21
PE20141382A1 (es) 2014-11-04
EP2694075A1 (en) 2014-02-12
BR112013025340A2 (pt) 2016-12-13
JP2016188255A (ja) 2016-11-04
JP2018052987A (ja) 2018-04-05
SG10201602569RA (en) 2016-05-30
DK2694075T3 (en) 2016-08-01
HK1194969A1 (zh) 2014-10-31
NZ615586A (en) 2015-02-27
KR101902325B1 (ko) 2018-09-28
PT2694075T (pt) 2016-07-11
KR20180108848A (ko) 2018-10-04
EA022434B1 (ru) 2015-12-30
CA2830822A1 (en) 2012-10-04
US11135205B2 (en) 2021-10-05
US20160185796A1 (en) 2016-06-30
KR20140023333A (ko) 2014-02-26

Similar Documents

Publication Publication Date Title
MX2013011132A (es) Inhibidor de fosfoinositida 3-quinasa con una porcion de enlace de cinc.
MD20150043A2 (ro) Inhibitori ai histon-demetilazelor
CY1121357T1 (el) Νεος ανοσοτροποποιητης και αντιφλεγμονωδεις ενωσεις
MY151556A (en) Organic compounds
NZ626618A (en) Hydroxamic acid derivatives and uses thereof
IN2014DN05772A (es)
TN2014000016A1 (en) 4 - piperidinyl compounds for use as tankyrase inhibitors
IN2014MN00988A (es)
GEP20146146B (en) Pyrrolopyrimidine compounds as inhibitors of cdk4/6
BR112012008073A2 (pt) compostos heterocíclicos como inibidores de janus quinase
UA110943C2 (uk) N-ацилсульфонамідні промотори апоптозу
MY172924A (en) Neprilysin inhibitors
IN2012MN02591A (es)
IN2014MN01183A (es)
MY170935A (en) Neprilysin inhibitors
MY167898A (en) Co-crystals and salts of ccr3-inhibitors
WO2013061004A8 (fr) Nouveaux composés di-substitués de la diamino-3,4-cyclobutène-3-dione-1,2 utiles dans le traitement de pathologies médiées par des chimiokines
BR112013019256A2 (pt) inibição de il-17 e ifn-gama para o tratamento de inflamação autoimune
WO2010150211A3 (en) Use of derivatives of indoles for the treatment of cancer
HK1211947A1 (en) Fluorinated epoxyketone-based compounds and uses thereof as proteasome inhibitors
MX343540B (es) Compuesto de tiazol y metodo de preparacion y uso del mismo.
MX2013002620A (es) Novedosas n-hidroxi-benzamidas para el tratamiento del cancer.
BR112012024586A2 (pt) compostos de purina
MX2013006670A (es) Derivado de 2-carboxamida-4-piperazinil-benzofurano.
WO2013071400A8 (en) Apocynin-lipoic acid conjugates and uses thereof cross-reference to related applications

Legal Events

Date Code Title Description
FG Grant or registration